Addressing Access Barriers in Relapsed and Refractory Multiple Myeloma

In this segment, Dr. Ajay Nooka asks Dr. Noopur Raje to discuss the system-level barriers that can impact access to advanced therapies in relapsed and refractory multiple myeloma. Dr. Raje highlights key challenges such as insurance approvals, treatment capacity constraints, and the need for reliable caregiver support, all of which can influence the timing and feasibility of therapy. She emphasizes that these barriers are often multifactorial and may vary between academic and community settings. The discussion also focuses on practical strategies to navigate these challenges, including early referral, proactive care coordination, and close collaboration with multidisciplinary teams. Dr. Raje underscores the importance of anticipating logistical hurdles and engaging support systems early to help ensure timely and appropriate treatment delivery. This segment highlights how addressing access-related barriers is essential to optimizing outcomes for patients with multiple myeloma.